6 recherche sur le mot-clé 'antibody'

Prenatal toxoplasmosis antibody and childhood autism / Marisa N. SPANN in Autism Research, 10-5 (May 2017)  

Public ISBD [article]  inAutism Research > 10-5 (May 2017) . - p.769-777 Titre : Prenatal toxoplasmosis antibody and childhood autism Type de document : texte imprimé Auteurs : Marisa N. SPANN, Auteur ; Andre SOURANDER, Auteur ; Heljä-Marja SURCEL, Auteur ; Susanna HINKKA-YLI-SALOMAKI, Auteur ; Alan S. BROWN, Auteur Article en page(s) : p.769-777 Langues : Anglais (eng) Mots-clés : toxoplasmosis  autism  antibody  childhood Index. décimale : PER Périodiques Résumé : There is evidence that some maternal infections during the prenatal period are associated with neurodevelopmental disorders, such as childhood autism. However, the association between autism and Toxoplasma gondii (T. gondii), an intracellular parasite, remains unclear. The authors examined whether serologically confirmed maternal antibodies to T. gondii are associated with odds of childhood autism in offspring. The study is based on a nested case-control design of a large national birth cohort (N = 1.2 million) and the national psychiatric registries in Finland. There were 874 cases of childhood autism and controls matched 1:1 on date of birth, sex, birthplace and residence in Finland. Maternal sera were prospectively assayed from a national biobank for T. gondii IgM and IgG antibodies; IgG avidity analyses were also performed. High maternal T. gondii IgM antibody was associated with a significantly decreased odds of childhood autism. Low maternal T. gondii IgG antibody was associated with increased offspring odds of autism. In women with high T. gondii IgM antibodies, the IgG avidity was high for both cases and controls, with the exception of three controls. The findings suggest that the relationship between maternal T. gondii antibodies and odds of childhood autism may be related to the immune response to this pathogen or the overall activation of the immune system. En ligne : http://dx.doi.org/10.1002/aur.1722 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=307 [article] Prenatal toxoplasmosis antibody and childhood autism [texte imprimé] / Marisa N. SPANN, Auteur ; Andre SOURANDER, Auteur ; Heljä-Marja SURCEL, Auteur ; Susanna HINKKA-YLI-SALOMAKI, Auteur ; Alan S. BROWN, Auteur . - p.769-777. Langues : Anglais (eng) in Autism Research > 10-5 (May 2017) . - p.769-777 Mots-clés : toxoplasmosis  autism  antibody  childhood Index. décimale : PER Périodiques Résumé : There is evidence that some maternal infections during the prenatal period are associated with neurodevelopmental disorders, such as childhood autism. However, the association between autism and Toxoplasma gondii (T. gondii), an intracellular parasite, remains unclear. The authors examined whether serologically confirmed maternal antibodies to T. gondii are associated with odds of childhood autism in offspring. The study is based on a nested case-control design of a large national birth cohort (N = 1.2 million) and the national psychiatric registries in Finland. There were 874 cases of childhood autism and controls matched 1:1 on date of birth, sex, birthplace and residence in Finland. Maternal sera were prospectively assayed from a national biobank for T. gondii IgM and IgG antibodies; IgG avidity analyses were also performed. High maternal T. gondii IgM antibody was associated with a significantly decreased odds of childhood autism. Low maternal T. gondii IgG antibody was associated with increased offspring odds of autism. In women with high T. gondii IgM antibodies, the IgG avidity was high for both cases and controls, with the exception of three controls. The findings suggest that the relationship between maternal T. gondii antibodies and odds of childhood autism may be related to the immune response to this pathogen or the overall activation of the immune system. En ligne : http://dx.doi.org/10.1002/aur.1722 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=307

Role for antibodies in altering behavior and movement / Jane E. LIBBEY in Autism Research, 3-4 (August 2010)  

Public ISBD [article]  inAutism Research > 3-4 (August 2010) . - p.147-152 Titre : Role for antibodies in altering behavior and movement Type de document : texte imprimé Auteurs : Jane E. LIBBEY, Auteur ; Robert S. FUJINAMI, Auteur Année de publication : 2010 Article en page(s) : p.147-152 Langues : Anglais (eng) Mots-clés : antibody autism chorea humoral-immunity systemic-lupus-erythematosus Index. décimale : PER Périodiques Résumé : At the past meeting of INSAR, the role of autoimmunity was discussed in an educational session. This article summarizes this discussion. In immune-mediated diseases, antibodies can contribute to the pathogenesis of the disease and are sometimes the force that drives the disease process. This concept has not been established for autism. In autoimmune diseases, such as systemic lupus erythematosus (SLE), antibodies are found to react with double-stranded DNA. These antibodies also cross-react with N-methyl-D aspartate receptors. Many SLE patients suffer neurologic syndromes of the central nervous system (CNS). Similarly individuals infected with Group A streptococcus (GAS) have antibodies against the GAS carbohydrate, which cross-react with tubulin and lysoganglioside GM1 on neurons. During the acute stage of infection, GAS-infected patients develop Syndenham chorea where the disease process is driven in part by these cross-reactive antibodies. As the antibody levels decrease, the clinical features of Syndenham chorea resolve. In these two immune-mediated diseases, antibodies clearly play a role in the pathogenesis of the diseases. There are reports that mothers of individuals with autism have antibodies that react with brain proteins and when these antibodies are passively transferred to pregnant non-human primates or rodents the offspring has behavioral and nervous system changes. It is still not clear whether the antibodies found in mothers of individuals with autism actually play a role in the disease. More studies need to be performed to identify the proteins recognized by the antibodies and to determine how these could affect development, behavior and changes within the CNS. En ligne : http://dx.doi.org/10.1002/aur.144 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=109 [article] Role for antibodies in altering behavior and movement [texte imprimé] / Jane E. LIBBEY, Auteur ; Robert S. FUJINAMI, Auteur . - 2010 . - p.147-152. Langues : Anglais (eng) in Autism Research > 3-4 (August 2010) . - p.147-152 Mots-clés : antibody autism chorea humoral-immunity systemic-lupus-erythematosus Index. décimale : PER Périodiques Résumé : At the past meeting of INSAR, the role of autoimmunity was discussed in an educational session. This article summarizes this discussion. In immune-mediated diseases, antibodies can contribute to the pathogenesis of the disease and are sometimes the force that drives the disease process. This concept has not been established for autism. In autoimmune diseases, such as systemic lupus erythematosus (SLE), antibodies are found to react with double-stranded DNA. These antibodies also cross-react with N-methyl-D aspartate receptors. Many SLE patients suffer neurologic syndromes of the central nervous system (CNS). Similarly individuals infected with Group A streptococcus (GAS) have antibodies against the GAS carbohydrate, which cross-react with tubulin and lysoganglioside GM1 on neurons. During the acute stage of infection, GAS-infected patients develop Syndenham chorea where the disease process is driven in part by these cross-reactive antibodies. As the antibody levels decrease, the clinical features of Syndenham chorea resolve. In these two immune-mediated diseases, antibodies clearly play a role in the pathogenesis of the diseases. There are reports that mothers of individuals with autism have antibodies that react with brain proteins and when these antibodies are passively transferred to pregnant non-human primates or rodents the offspring has behavioral and nervous system changes. It is still not clear whether the antibodies found in mothers of individuals with autism actually play a role in the disease. More studies need to be performed to identify the proteins recognized by the antibodies and to determine how these could affect development, behavior and changes within the CNS. En ligne : http://dx.doi.org/10.1002/aur.144 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=109

Autism spectrum disorders are associated with an elevated autoantibody response to tissue transglutaminase-2 / Allen J. ROSENSPIRE in Autism Research, 4-4 (August 2011)  

Public ISBD [article]  inAutism Research > 4-4 (August 2011) . - p.242-249 Titre : Autism spectrum disorders are associated with an elevated autoantibody response to tissue transglutaminase-2 Type de document : texte imprimé Auteurs : Allen J. ROSENSPIRE, Auteur ; Wonsuk YOO, Auteur ; Sherri MENARD, Auteur ; Anthony R. TORRES, Auteur Année de publication : 2011 Article en page(s) : p.242-249 Langues : Anglais (eng) Mots-clés : immunology  anti-transglutaminase antibody  pediatrics Index. décimale : PER Périodiques Résumé : We report that a significant number of autistic children have serum levels of IgA antibodies above normal to the enzyme tissue transglutaminase II (TG2), and that expression of these antibodies to TG2 is linked to the (HLA)-DR3, DQ2 and DR7, DQ2 haplotypes. TG2 is expressed in the brain, where it has been shown to be important in cell adhesion and synaptic stabilization. Thus, these children appear to constitute a subpopulation of autistic children who fall within the autism disease spectrum, and for whom autoimmunity may represent a significant etiological component of their autism. En ligne : http://dx.doi.org/10.1002/aur.194 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=141 [article] Autism spectrum disorders are associated with an elevated autoantibody response to tissue transglutaminase-2 [texte imprimé] / Allen J. ROSENSPIRE, Auteur ; Wonsuk YOO, Auteur ; Sherri MENARD, Auteur ; Anthony R. TORRES, Auteur . - 2011 . - p.242-249. Langues : Anglais (eng) in Autism Research > 4-4 (August 2011) . - p.242-249 Mots-clés : immunology  anti-transglutaminase antibody  pediatrics Index. décimale : PER Périodiques Résumé : We report that a significant number of autistic children have serum levels of IgA antibodies above normal to the enzyme tissue transglutaminase II (TG2), and that expression of these antibodies to TG2 is linked to the (HLA)-DR3, DQ2 and DR7, DQ2 haplotypes. TG2 is expressed in the brain, where it has been shown to be important in cell adhesion and synaptic stabilization. Thus, these children appear to constitute a subpopulation of autistic children who fall within the autism disease spectrum, and for whom autoimmunity may represent a significant etiological component of their autism. En ligne : http://dx.doi.org/10.1002/aur.194 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=141

Recent progress and considerations for AAV gene therapies targeting the central nervous system / Erik Allen LYKKEN in Journal of Neurodevelopmental Disorders, 10-1 (December 2018)  

Public ISBD [article]  inJournal of Neurodevelopmental Disorders > 10-1 (December 2018) . - 16 p. Titre : Recent progress and considerations for AAV gene therapies targeting the central nervous system Type de document : texte imprimé Auteurs : Erik Allen LYKKEN, Auteur ; Charles SHYNG, Auteur ; Reginald James EDWARDS, Auteur ; Alejandra ROZENBERG, Auteur ; Steven James GRAY, Auteur Année de publication : 2018 Article en page(s) : 16 p. Langues : Anglais (eng) Mots-clés : Aav9  Adeno-associated virus  Cellular immunity  Central nervous system  Clinical trial  Gene therapy  Neutralizing antibody Index. décimale : PER Périodiques Résumé : BACKGROUND: Neurodevelopmental disorders, as a class of diseases, have been particularly difficult to treat even when the underlying cause(s), such as genetic alterations, are understood. What treatments do exist are generally not curative and instead seek to improve quality of life for affected individuals. The advent of gene therapy via gene replacement offers the potential for transformative therapies to slow or even stop disease progression for current patients and perhaps minimize or prevent the appearance of symptoms in future patients. MAIN BODY: This review focuses on adeno-associated virus (AAV) gene therapies for diseases of the central nervous system. An overview of advances in AAV vector design for therapy is provided, along with a description of current strategies to develop AAV vectors with tailored tropism. Next, progress towards treatment of neurodegenerative diseases is presented at both the pre-clinical and clinical stages, focusing on a few select diseases to highlight broad categories of therapeutic parameters. Special considerations for more challenging cases are then discussed in addition to the immunological aspects of gene therapy. CONCLUSION: With the promising clinical trial results that have been observed for the latest AAV gene therapies and continued pre-clinical successes, the question is no longer whether a therapy can be developed for certain neurodevelopmental disorders, but rather, how quickly. En ligne : http://dx.doi.org/10.1186/s11689-018-9234-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=386 [article] Recent progress and considerations for AAV gene therapies targeting the central nervous system [texte imprimé] / Erik Allen LYKKEN, Auteur ; Charles SHYNG, Auteur ; Reginald James EDWARDS, Auteur ; Alejandra ROZENBERG, Auteur ; Steven James GRAY, Auteur . - 2018 . - 16 p. Langues : Anglais (eng) in Journal of Neurodevelopmental Disorders > 10-1 (December 2018) . - 16 p. Mots-clés : Aav9  Adeno-associated virus  Cellular immunity  Central nervous system  Clinical trial  Gene therapy  Neutralizing antibody Index. décimale : PER Périodiques Résumé : BACKGROUND: Neurodevelopmental disorders, as a class of diseases, have been particularly difficult to treat even when the underlying cause(s), such as genetic alterations, are understood. What treatments do exist are generally not curative and instead seek to improve quality of life for affected individuals. The advent of gene therapy via gene replacement offers the potential for transformative therapies to slow or even stop disease progression for current patients and perhaps minimize or prevent the appearance of symptoms in future patients. MAIN BODY: This review focuses on adeno-associated virus (AAV) gene therapies for diseases of the central nervous system. An overview of advances in AAV vector design for therapy is provided, along with a description of current strategies to develop AAV vectors with tailored tropism. Next, progress towards treatment of neurodegenerative diseases is presented at both the pre-clinical and clinical stages, focusing on a few select diseases to highlight broad categories of therapeutic parameters. Special considerations for more challenging cases are then discussed in addition to the immunological aspects of gene therapy. CONCLUSION: With the promising clinical trial results that have been observed for the latest AAV gene therapies and continued pre-clinical successes, the question is no longer whether a therapy can be developed for certain neurodevelopmental disorders, but rather, how quickly. En ligne : http://dx.doi.org/10.1186/s11689-018-9234-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=386

Serological surveillance of children with CSF shunting devices / R. BAYSTON in Developmental Medicine & Child Neurology, S35 (December 1975)

Public ISBD [article]  inDevelopmental Medicine & Child Neurology > S35 (December 1975) . - p.104-110 Titre : Serological surveillance of children with CSF shunting devices Type de document : texte imprimé Auteurs : R. BAYSTON, Auteur Année de publication : 1975 Article en page(s) : p.104-110 Langues : Anglais (eng) Mots-clés : A naturally-occurring, age-related rise in titre of antibody to Staph. albus in both hydrocephalic and non-hydrocephalic children is demonstrated in this report. In view of this finding, the value of serial determinations of antibody titre in children with shunts is discussed in terms of an organised surveillance programme. Index. décimale : PER Périodiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=451 [article] Serological surveillance of children with CSF shunting devices [texte imprimé] / R. BAYSTON, Auteur . - 1975 . - p.104-110. Langues : Anglais (eng) in Developmental Medicine & Child Neurology > S35 (December 1975) . - p.104-110 Mots-clés : A naturally-occurring, age-related rise in titre of antibody to Staph. albus in both hydrocephalic and non-hydrocephalic children is demonstrated in this report. In view of this finding, the value of serial determinations of antibody titre in children with shunts is discussed in terms of an organised surveillance programme. Index. décimale : PER Périodiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=451

Serum Levels of S100b, Interleukin-6 and Anti-Transglutaminase Ii IgA as Immune Markers in a Sample of Egyptian Children with Autistic Spectrum Disorders / N.M. SHAKER in Autism - Open Access, 6-5 ([01/09/2016])  

Permalink